Scientists at Newcastle University have developed a cancer fighting technology which uses UV light to activate antibodies which very specifically attack tumours.
Therapeutic antibodies have long been recognised as having excellent potential but getting them to efficiently target tumour cells has proved to be very difficult.
Now, Professor Colin Self and Dr Stephen Thompson from Newcastle University have developed a procedure to cloak antibodies which can then be activated by UV-A light and so can be targeted to a specific area of the body just by shining a probe at the relevant part.
This procedure maximizes the destruction of the tumour while minimising damage to healthy tissue.
Professor Self says, I would describe this development as the equivalent of ultra-specific magic bullets. This could mean that a patient coming in for treatment of bladder cancer would receive an injection of the cloaked antibodies. She would sit in the waiting room for an hour and then come back in for treatment by light. Just a few minutes of the light therapy directed at the region of the tumour would activate the T-cells causing her bodys own immune system to attack the tumour.
The details are contained in two papers* published online today in the journal ChemMedChem.
The Newcastle University researchers demonstrate in the first paper the procedure of coating the surface of a protein, such as an antibody, with an organic oil which is photocleavable, a process called cloaking. This prevents the antibody reacting within the body unless it is illuminated.
When UV-A light is shone onto the cloaked antibody it is activated. The activated antibody binds to T-cells, the bodys own defence system, triggering the T-cells to target the surrounding tissue.
In the second paper, they demonstrate that when the cloaked antibodies are activated by light near a tumour, the tumour is killed. This work means that antibodies c
'/>"/>
| Contact: Karen Bidewell press.office@ncl.ac.uk 01-912-226-972 Newcastle University Source:Eurekalert |